Stay updated on Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial
Sign up to get notified when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.
Latest updates to the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page
- CheckyesterdayChange DetectedThe website has updated the contact details section for the study, now providing information on who to contact for questions about joining the study and where it is taking place, reflecting a revision from v2.12.2 to v2.13.2.SummaryDifference2%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe website has added new features, while several detailed options for data download and participant information have been removed.SummaryDifference3%
- Check22 days agoChange DetectedThe website has been updated to version v2.12.2, adding new features for downloading study data in various formats and including detailed participant and study information, while removing the previous version v2.12.1.SummaryDifference3%
- Check37 days agoChange DetectedThe website has been updated from version 2.12.0 to 2.12.1.SummaryDifference0.1%
- Check44 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential enhancements or features.SummaryDifference0.1%
- Check66 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.1%
Stay in the know with updates to Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.